Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent

Bone Marrow Transplantation

Volumn 25, Issue 12, 2000, Pages 1319-1320

  Zomas, A ^a,c   Anagnostopoulos, N ^a   Dimopoulos, M A ^b  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c NONE   (Greece)

Author keywords

Multiple myeloma; Thalidomide

Indexed keywords

DEXAMETHASONE; THALIDOMIDE;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD CELL COUNT; CASE REPORT; HUMAN; MALE; MULTIPLE MYELOMA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RELAPSE; REMISSION;

EID: 0033918032     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702444     Document Type: Article

References (6)

1. Mehta J, Singhal S. Graft-versus-myeloma. Bone Marrow Transplant 1998; 22: 835-843.
2. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New Engl J Med 1996; 335: 91-97.
3. Mehta J, Tricot G, Jagannath S et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant 1998; 21: 887-892.
4. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. New Engl J Med 1999; 341: 1565-1571.
5. D'Amato RJ, Loughman MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4085.
6. Vacca A, Ribatti D, Presta M et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999; 93: 3064-3073.